Buy the Dip: Regeneron Looks Oversold After a Narrow Melanoma Miss
Regeneron plunged after a Phase 3 fianlimab combination narrowly missed statistical significance for PFS (p=0.0627). The drop creates a tactical buying opportunity. The company still generates strong free cash flow, has low leverage, and multiple near-term catalysts. This trade idea grades REGN higher and lays out entry, stop, and target levels acr…